A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin
This study is currently recruiting participants.
Verified May 2013 by Hoffmann-La Roche
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01729403
First received: November 14, 2012
Last updated: May 7, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This single-center, randomized, double-blind, placebo-controlled study will evaluate the effect of aleglitazar on insulin sensitivity in patients with type 2 diabetes mellitus who are inadequately controlled on metformin monotherapy. Patients will be randomized to receive either aleglitazar 150 mcg or placebo orally daily for 16 weeks, in addition to their existing dose and regimen of metformin.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Type 2 |
Drug: aleglitazar Drug: placebo Drug: metformin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A SINGLE CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY |
Resource links provided by NLM:
Further study details as provided by Hoffmann-La Roche:
Primary Outcome Measures:
- Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate) [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Change in hepatic insulin sensitivity (basal index of hepatic insulin resistance) [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in parameters of beta cell function (first and second phase insulin secretion) [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in HbA1c [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in lipid profile [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in mean 24h blood pressure [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in hepatic fat content measured by magnetic resonance spectroscopy (MRI) [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in fat content/distribution in the abdominal region measured by MRI [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in total body fat content measured by air displacement phlethysmography [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in homeostatic indexes of insulin sensitivity assessed by HOMA-IS [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Change in markers of cardiovascular risk (high sensitivity C-reactive protein, adiponectin, free fatty acid) [ Time Frame: from baseline to Week 16 ] [ Designated as safety issue: No ]
- Safety: Incidence of adverse events [ Time Frame: 22 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 80 |
| Study Start Date: | December 2012 |
| Estimated Study Completion Date: | May 2014 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Aleglitazar |
Drug: aleglitazar
150 mcg orally daily, 16 weeks
Drug: metformin
patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
|
| Placebo Comparator: Placebo |
Drug: placebo
orally daily, 16 weeks
Drug: metformin
patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
|
Eligibility| Ages Eligible for Study: | 30 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult patients, 30 to 70 years of age inclusive at screening
- Type 2 diabetes mellitus patients treated with stable metformin therapy for at least 12 weeks prior to screening; metformin dose should not exceed the maximum dose specified in the label
- HbA1c >/= 6.5% and </= 9% at screening and baseline
- Fasting plasma glucose </= 13.3 mmol/L (</= 240 mg/dl) at screening and baseline
- Body mass index (BMI) >/= 25 at screening; BMI >/= 27 for subjects with HbA1c < 7%
- Stable weight +/- 5% for at least 12 weeks prior to screening
Exclusion Criteria:
- Women who are pregnant, intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods
- Diagnosis or history of type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months
- Any previous treatment with a thiazolidinedione or with a dual PPAR agonist
- Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (>/= 1 month) statin therapy
- History of bariatric surgery or currently undergoing evaluation for bariatric surgery
- Prior intolerance to fibrate
- Treatment with any anti-diabetic medication other than metformin in the last 12 weeks prior to screening and/or herbal/over-the-counter preparations that may affect glycemic control within 12 weeks prior to screening
- Clinically apparent liver disease
- Positive for hepatitis B, hepatitis C or HIV infection
- Clinical evidence of anemia
- Symptomatic congestive heart failure (New York Heart Association Class II-IV) at screening
- Myocardial infarction, acute coronary syndrome, or transient ischemic attack/stroke within 6 months prior to screening
- Known macular edema at screening or prior to screening visit
- Uncontrolled hypertension despite stable (for at least 4 weeks) anti-hypertensive treatment
- Diagnosed and/or treated malignancy (except for treated cases of basal cell skin cancer, in situ carcinoma of the cervix or in situ prostate cancer) within the past 5 years
- Chronic oral or parenteral corticosteroid treatment (> 2 weeks) within 3 months prior to screening
- History of active substance abuse (including alcohol) within the past 2 years or positive test result for drugs of abuse or alcohol prior to first dosing
- Presence of any absolute or relative contraindication for the conduct of magnetic resonance imaging (MRI) investigation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01729403
Contacts
| Contact: Please reference Study ID Number: WC28038 www.roche.com/about_roche/roche_worldwide.htm | 888-662-6728 (U.S. Only) | genentechclinicaltrials@druginfo.com |
Locations
| Germany | |
| Recruiting | |
| Neuss, Germany, 41460 | |
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
More Information
No publications provided
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT01729403 History of Changes |
| Other Study ID Numbers: | WC28038 |
| Study First Received: | November 14, 2012 |
| Last Updated: | May 7, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Insulin Resistance Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Hyperinsulinism Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013